Sign in

You're signed outSign in or to get full access.

Jeff Huber

Director at Summit Therapeutics
Board

About Jeff Huber

Jeff Huber (age 56) has served as an independent director of Summit Therapeutics since June 2024; he is Audit Committee Chair and designated the Audit Committee financial expert. He is co-founder and Managing Director of Triatomic Capital (since 2022), previously Vice Chairman and Founding CEO of GRAIL (2016–2021; Founding CEO 2016–2017), and held senior roles at Alphabet/Google (SVP, 2003–2016), eBay (VP Architecture & Systems, 2001–2003), and Excite@Home; he holds a B.S. in Computer Engineering (University of Illinois) and an MBA (Harvard). The Board has determined Huber is independent under Nasdaq rules.

Past Roles

OrganizationRoleTenureCommittees/Impact
Triatomic Capital Private LPCo-founder & Managing DirectorSince 2022Private investing firm leadership
GRAIL, Inc.Vice Chairman; Founding CEO2016–2021; 2016–2017Led early cancer detection platform
Alphabet Inc. (Google)Senior Vice President2003–2016Executive leadership in technology scale-up
eBay Inc.VP, Architecture & Systems Development2001–2003Platform architecture
Excite@HomeSVP, EngineeringNot disclosedSenior engineering leadership

External Roles

OrganizationRoleTenureCommittees/Impact
Electronic Arts Inc. (public)DirectorCurrentBoard oversight
Upstart Holdings Inc. (public)DirectorCurrentBoard oversight
Mammoth Bio; d‑Matrix; Manifold Bio; Openwater; Genalyte; Weta Digital (private)Board memberNot disclosedTech/biotech innovation networks
Aldevron (private)Director2019–2021Biotech manufacturing governance
Zapata Computing Holdings Inc. (public)Director2021–2024AI/quantum software oversight

Board Governance

  • Independence: Board determined Huber is independent under Nasdaq rules.
  • Committee assignments: Audit Committee Chair; Audit members are Huber (Chair), Booth, Ronaghi; Huber qualifies as Audit Committee financial expert.
  • Attendance: In 2024, the Board held 2 meetings; each director attended at least 75% of board and applicable committee meetings; all current Board members attended the 2024 annual meeting.
  • Committee activity: 2024 meetings—Audit: 6; Compensation: 1; Nominating & Corporate Governance: 0.
  • Lead Independent Director: Kenneth A. Clark is appointed Lead Independent Director.
  • Controlled company status: Summit is a “controlled company” under Nasdaq due to majority voting power held by Robert W. Duggan; while not currently using all exemptions, the company has relied on some and may do so in the future.
  • Insider trading policy: Prohibits short sales, derivatives (puts/calls), and direct hedging transactions in company securities.

Fixed Compensation

ComponentAmount/TermsNotes
Annual Board retainer (cash)$49,900Paid quarterly
Committee membership fee (each committee)$6,500Annual, per committee
Committee Chair feesAudit: $36,700; Compensation: $13,000; Nominating: $13,000Annual
2024 cash fees actually earned (Huber)$39,055Reported in 2024 Director Compensation

Performance Compensation

Equity ComponentGrant detailVesting/Terms2024 Value/Counts
Annual director option grant35,000 optionsVests in four equal quarterly installments; strike = FMV at grantProgram terms
New director grant (Huber, 2024)200,000 optionsVests in four equal annual installments; first tranche at 1-year anniversary; strike = FMV at grantProgram terms
Retainer Option ElectionCash-to-option conversion at 2.0x multiplier; annual awardVests quarterly; 10-year termProgram terms
2024 option award (Huber)Option Awards fair value: $1,507,113
Options outstanding (Huber, 12/31/2024)217,883Exercisable: 17,883

Other Directorships & Interlocks

EntityTypeRelationshipNote
Electronic Arts Inc.PublicDirectorCurrent role
Upstart Holdings Inc.PublicDirectorCurrent role
GRAIL, Inc.Private (historical)Huber: Founding CEO/Vice Chair; Ronaghi: Co-founderHistorical overlap with fellow SMMT director Mostafa Ronaghi (interlock signal)

Expertise & Qualifications

  • Audit Committee financial expert designation; financial literacy confirmed by the Board.
  • Deep technology and healthcare leadership background spanning large-scale platforms and life sciences innovation.
  • Education: B.S. in Computer Engineering (University of Illinois); MBA (Harvard Business School).

Equity Ownership

HolderShares OwnedOptions exercisable within 60 daysTotal Beneficial Ownership% of Class
Jeff Huber (as of April 15, 2025)50,05226,63376,685<1%
Jeff Huber (as of Dec 31, 2024)Options outstanding: 217,883; Exercisable: 17,883

Governance Assessment

  • Strengths: Independent audit chair with financial expert status; Audit Committee met six times in 2024 indicating robust oversight; clear prohibitions on hedging/derivatives in Insider Trading Policy; Lead Independent Director structure in place.
  • Alignment: Director pay is heavily equity-oriented for Huber in 2024 (cash $39,055 versus option award fair value $1,507,113), and program allows conversion of cash retainers into options (2.0x multiplier), increasing ownership alignment.
  • Attendance & engagement: Board convened 2 times in 2024; all directors met at least 75% attendance, and Audit Committee met 6 times under Huber’s chairmanship—solid engagement for audit oversight.
  • Potential conflicts/related-party exposure: No related-party transactions involving Huber are disclosed; related-party items center on Duggan, Zanganeh (bridge notes, warrants, office subleases), Xia/Akeso (license & payments), Soni (share purchases), and Clark/WSGR (legal services).
  • Risk indicators and red flags:
    • Controlled company status may reduce certain Nasdaq governance protections; the company may rely on exemptions in the future (investor vigilance warranted).
    • Pending derivative litigation related to December 2022 bridge financing notes (fiduciary duty claims) creates governance overhang; Huber is part of the Board’s oversight environment as Audit Chair. Defendants plan to move to dismiss.
    • Personal ownership remains small (<1%), which is typical for outside directors but provides limited “skin-in-the-game” relative to controlling shareholders.
  • Shareholder signals: Strong say-on-pay support (≈97% approval in 2024) provides a positive governance sentiment backdrop, though not director-specific.